Short answer
Insmed Incorporated (INSM) filed its Q2 2025 10-Q quarterly report on Aug 7, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $107M (up 18.9% year over year) with net income of −$322M.
Q2 2025 key financials · XBRL
- Revenue
- $107M
- +18.9% YoY · +15.7% QoQ
- Net income
- −$322M
- −7.0% YoY · −25.4% QoQ
- Operating margin
- -291.3%
- EPS (diluted)
- −$1.70
- +13.3% YoY · −19.7% QoQ
Source: XBRL data from the Insmed Incorporated (INSM) Q2 2025 10-Q on SEC EDGAR. USD.
Insmed Incorporated Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes in risk factors since 10-K filed February 20, 2025
- Continued risk from clinical trial uncertainties impacting regulatory approval timelines
- Dependence on limited product candidates heightening risk of revenue shortfall if trials fail
- Potential regulatory changes affecting drug pricing and reimbursement policies remain key concern
- Liquidity risks persist due to limited operating history and reliance on external financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insmed Incorporated quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.